Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,405,694 | $1,780,498 | $1,971,219 | $1,684,945 |
| - Cash | $47,120 | $73,048 | $53,104 | $71,335 |
| + Debt | $6,276 | $110,163 | $110,800 | $110,585 |
| Enterprise Value | $2,364,850 | $1,817,613 | $2,028,915 | $1,724,195 |
| Revenue | $99,219 | $81,504 | $65,846 | $71,360 |
| % Growth | 21.7% | 23.8% | -7.7% | – |
| Gross Profit | $90,534 | $74,012 | $57,016 | $64,455 |
| % Margin | 91.2% | 90.8% | 86.6% | 90.3% |
| EBITDA | $11,123 | -$11,952 | -$18,667 | -$4,456 |
| % Margin | 11.2% | -14.7% | -28.3% | -6.2% |
| Net Income | $7,410 | -$15,886 | -$25,060 | -$10,788 |
| % Margin | 7.5% | -19.5% | -38.1% | -15.1% |
| EPS Diluted | 0.06 | -0.13 | -0.2 | -0.089 |
| % Growth | 146.2% | 35% | -124.2% | – |
| Operating Cash Flow | -$1,754 | $324 | -$30,380 | -$748 |
| Capital Expenditures | $0 | -$78 | -$608 | -$5,000 |
| Free Cash Flow | -$1,754 | $246 | -$30,988 | -$5,748 |